[New substances in oncologic therapy].
D006585:Altretamine / Q000627:therapeutic use; D003504:Ancitabine / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000379:methods; D005047:Etoposide / Q000627:therapeutic use; D006801:Humans; D008936:Mitolactol / Q000627:therapeutic use; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D011929:Razoxane / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013629:Tamoxifen / Q000627:therapeutic use; D013997:Time Factors; D014748:Vinca Alkaloids / Q000627:therapeutic use; D009353:Zinostatin / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D014748:Vinca Alkaloids; D013629:Tamoxifen; D011929:Razoxane; D005047:Etoposide; D003606:Dacarbazine; D004317:Doxorubicin; D009353:Zinostatin; D003504:Ancitabine; D008936:Mitolactol; D001374:Azacitidine; D002945:Cisplatin; D006585:Altretamine
Neue Substanzen in der onkologischen Therapie.